INPHOG-AML-23-02

Indian Childhood Acute Promyelocytic Leukemia Study (I-ChAMPs)

PI : Dr. Smita Kayal

Institution : Jawaharlal Institute of Postgraduate Medical Education & Research

About the Study

This study focuses on improving treatment and outcomes in children with Acute Promyelocytic Leukemia (APML) by providing standardized care and developing a national registry with well-documented clinical data.

Aim of the Study

Provide standardized treatment (standard of care) for pediatric APML across India.
Develop a national registry with detailed clinical data.
Improve survival outcomes and expand access to care for children and adolescents with APML.

Eligibility Criteria

Inclusion Criteria

Newly-diagnosed acute promyelocytic leukemia (APML), age 0-19 years signed written informed consent (waiver of consent for retrospective cohort).

Exclusion Criteria

With respect to the primary purpose of the registry no exclusion criteria are specified.
Explicitly patients with unsuitability for intensive therapy, pre –induction deaths should also be recorded in the registry including patients who refuse treatment, for any reason.